Buy PharmaCyte Biotech

In: Tips

25 Mar 2015

Hi Everybody,

Everyday there’s a new biotech running, creating profit opportunities for savvy traders.

With this in mind we found a nice looking biotech, that has received FDA orphan drug designation for their pancreatic cancer treatment. They are in phase 2b of clinical trials which are expected to commence this year.

That’s not all, this pancreatic treatment is based on the company’s cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R) which may also be useful in treatment for other forms of cancer as well as diabetes.

The fact is this company has a real shot at making some waves as larger investors are more willing to take chances on little known biotechs due to the current market condition.

Our alert for Wednesday is:
PharmaCyte Biotech, Inc.
Ticker symbol: PMCB
Last price: $0.10

PMCB is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R).

PMCB’s patented Cell-in-a-Box treatment, has earned FDA ‘orphan drug designation’, for the treatment of pancreatic cancer. They will be executing Phase 2b of their clinical trials vs. a treatment using Eli Lilly’s Gemzar and Celgene’s Abraxane®.

Celgene is a billion dollar market cap company, and Eli Lilly is even bigger…if PMCB’s trials are successful this could end up as a wild ride for early investors.

But even before any of that happens, the sheer potential of this story as it makes its rounds could make for some major price swings.

The smallcap biotech sector is leading the market, and PMCB is a beautiful opportunity at capitalizing on this trend.

Make sure you’re ready to book your profits with PMCB!

Free Stock TipsAs always, do your own research, don’t chase gaps, use limit orders to enter positions, always use stop loss orders to protect your position, and take profits when you are in a position to do so.

Good Trading

Hi Everybody,

The future looks bright for our alert for Wednesday. If you take a look at their recent numbers you will see why investors will be trampling over each other to buy shares in this up and coming solar company.

This company’s numbers tell the story:
• 19 consecutive quarters of improvement.
• 3 profitable quarters in a row.
• $5.4 million in sales for the first 9 months of 2014 (up almost 100% from 2013).
• $971,594 in profits for the first 9 months of 2014.

Our alert for Wednesday is:
Atlantic Wind & Solar, Inc.
Ticker symbol: AWSL
Last price: $0.34

AWSL is renewable energy asset developer, with emphasis on photovoltaic solar (PV) and wind energy.

AWSL’s portfolio is diversified across 22 municipalities in Canada and 5 regions in Central and South America including, Ecuador and Peru.

The growth of the global renewable energy industry has soared over the past decade yet it is still in its infancy.

AWSL is based in Canada which means big opportunities. Canada is a world leader in the production and use of energy from renewable resources. As a matter of fact, wind and solar photovoltaic energy are the fastest growing sources of electricity currently providing about 16.9% of the country’s total primary energy supply.

Recent News:
• Atlantic Wind & Solar Supplies More Power to the Ontario Power Authority.
• AWSL announced the addition of another utility scale solar plant in Ontario, Canada now powering the grid. The formal receipt of a notice of Commercial Operation (COD) from the Ontario Power Authority (OPA) marks the final step in the construction and connection of this solar plant.
• The solar power plant was developed by its Canadian subsidiary Atlantic Solar Inc.
• The photovoltaic plant consists of a 111.585 KW AC / 132.345 KW DC fixed array of 255W poly-crystalline modules. The power will be sold to the Ontario Power Authority for 20 years at a rate of $0.713/kWh.

Conclusion:
• AWSL is clearly a well run company and has the numbers to prove it.
• AWSL continues to sign agreements that will provide long term cash flow to the company and their portfolio continues to grow.
• There should be new numbers out soon, and because AWSL has improved 19 quarters in a row, it is pretty safe to say, they should be strong.
• With more and more investors learning about AWSL over the next few days this sleepy little stock is sure to get moving creating HUGE profit opportunities for those that get on board.

Make sure you’re ready to book your profits with AWSL!

Free Stock TipsAs always, do your own research, don’t chase gaps, use limit orders to enter positions, always use stop loss orders to protect your position, and take profits when you are in a position to do so.

Good Trading

Buy NHale – Again!

In: Tips

5 Mar 2015

Hi Everybody,

We hope you managed to get on to yesterdays alert. VTEQD opened at .033 then traded to a high of .075 for a 127% price gain.

Let’s move on to another opportunity we’ve been following, it looks positioned for its next move.

Remember NHLE our pick from last week? That stock traded up 50% in just 2 days.

Well, NHLE has come back down to its major support area and should bounce, setting up a sweet trade.

If you missed last weeks trade, here is another opportunity to catch these easy gains!

If you missed last week’s alert, take a look at it here: http://www.stips.com/share-stock-tips/buy-nhale-2/

Highlights
• This company is a medical marijuana company.
• They are actively seeking acquisitions.

Our alert for Thursday is:
NHale, Inc.
Ticker symbol: NHLE
Last price: $0.112

NHLE acquires companies within the medical and recreational cannabis market.

NHLE announced last week that they project revenues exceeding $30 million in 2015. Those numbers should really excite any trader learning about this opportunity.

Make sure you’re ready to book your profits with NHLE!

Free Stock TipsAs always, do your own research, don’t chase gaps, use limit orders to enter positions, always use stop loss orders to protect your position, and take profits when you are in a position to do so.

Good Trading

Buy VeriTeQ

In: Tips

4 Mar 2015

Hi Everybody,

Our alert for Wednesday looks amazing. We think we found a real gem here, the stock appears to be extremely undervalued based on recent news and traders taking positions at these levels will see tremendous upside.

Highlights:
• This company is a medical device company with FDA approved products.
• The US government passed legislation that should drive sales.
• This company is a potential takeover candidate.

Our alert for Wednesday is:
VeriTeQ Corporation
Ticker symbol: VTEQD
Last price: $0.03

VTEQD develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment.

VTEQD has proprietary technology, including over 100 patents, patents pending, patent licenses, and U.S. Food and Drug Administration cleared and CE marked products.

VTEQD has two principal business lines:
1. Unique Device Identification (UDI) for medical devices
2. Radiation dosimeters and other medical sensor applications.

What’s most interesting is their UDI technology. Branded as Q Inside Safety Technology, these little RFID chips VTEQD produces are placed in medical products such as breast implants.

One major issue this helps resolve is when there is a recall. Without the RFID tech, when there is a recall on a certain line of implants there’s no real way of knowing if someone’s implant should be recalled. With VTEQD’s UDI technology this will no longer be an issue.

Not only does it solve this problem, this kind of UDI technology is now being mandated by the FDA for reusable devices such as implant ‘sizers’.

In September 2013 FDA issued a Final Rule (“Rule”) which will require most medical devices sold in the U.S. to carry a UDI.

Now here’s where it gets interesting…

VeriTeQ Corporation executes term sheet for exclusive license of its Q Inside Safety Technology for the breast implant market with a $1.75 million up front payment.

VTEQD’s market cap is 42K. Can you say ‘undervalued’?

Not to mention, 80% of the breast implant market is controlled by Mentor and Allergen. Given the FDA requirements, and the cost of developing a technology like VTEQD’s, it would stand to reason that these two giants may take a long look at VTEQD as a possible acquisition.

All of these factors along with the fact the stock is only 3 cents a share make VTEQD a very intriguing opportunity. As more investors learn about this story the rush could create some huge price appreciation relatively quickly.

Make sure you’re ready to book your profits with VTEQD.

Free Stock TipsAs always, do your own research, don’t chase gaps, use limit orders to enter positions, always use stop loss orders to protect your position, and take profits when you are in a position to do so.

Good Trading

Buy NHale

In: Tips

24 Feb 2015

Hi Everybody,

Monday’s alert gained 33%, and our alert for Tuesday has the potential for big gains too, so let’s get right to it.

Highlights:
• This company is a medical marijuana company.
• They are actively seeking acquisitions.

Our alert for Tuesday is:
NHale, Inc.
Ticker symbol: NHLE
Last price: 11.8 cents

NHLE acquires companies within the medical and recreational cannabis market.

NHLE projects revenues exceeding $30 million in 2015! Those numbers should really excite any new trader learning about this opportunity.

NHLE CEO Lance Williams has 12 years experience in indoor agriculture and is referred to as a “Master Grower”, so this isn’t just some company trying to ride the cannabis wave. NHLE brings expertise to the market which should help them rise above the pack.

Toronto based investment group, Four Twenty Investments, certainly believes NHLE has explosive potential. They just committed 10 million dollars to NHLE to make more acquisitions.

NHLE is in the process of evaluating possible acquisitions.

You know what that means? Even more potential press releases that could send this stock flying.

With this big news, NHLE is sitting pretty and traders are on the edge of their seats, which means we may have a serious jump in liquidity and volatility this week.

Make sure you’re ready to book your profits with NHLE!

Free Stock TipsAs always, do your own research, don’t chase gaps, use limit orders to enter positions, always use stop loss orders to protect your position, and take profits when you are in a position to do so.

Good Trading

Hi Everybody,

If you liked Friday’s 15% gainer, you will love Monday’s alert.

Highlights:
• This stock trades under 1 cents.
• This stock has shown the ability to make gains for traders

Our alert for Monday is:
Definitive Rest Mattress Company, Inc.
Ticker symbol: DRMC
Last price: 0.0052

DRMC recently announced their plans to enter the billion dollar metal works industry for commercial aircraft and aerospace industries.

DRMC sees a great opportunity for revenue in these sectors, and plans to capitalize immediately through the acquisition of companies with strong growth and profit potential.

Their first acquisition:
NU Metals Technology
• Aerospace, commercial, industrial manufacturing, distribution and sales
• Company formed by industry veterans
• Combined 50 years of experience in the metals sales and CNC manufacturing industry

The aviation industry needs to replace older, less efficient airplanes to reduce the cost of air travel.

Industry experts forecast a long-term demand for 35,280 new airplanes, valued at $4.8 trillion.

That’s a pretty big demand pie DRMC’s new subsidiary is looking to take a bite of.

But look, we’re not telling you this is likely or not, what we are telling you is this particular setup seems to be making traders money, and you have an opportunity to benefit immediately on Monday.

Make sure you’re ready to book your profits with DRMC!

Free Stock TipsAs always, do your own research, don’t chase gaps, use limit orders to enter positions, always use stop loss orders to protect your position, and take profits when you are in a position to do so.

Good Trading

Buy Cre8tive Works

In: Tips

20 Feb 2015

Hi Everybody,

Many of you have sent emails asking for a quick trade idea to put some cash in your pockets, so here you go.

Highlights
• This stock trades under 2 cents.
• This stock has a history of making 50%, 100%, even a 400% move in a single day.
• There are lots of newsletters talking this one up tonight which means tomorrow should be a big day.

Our alert for Friday is:
Cre8tive Works, Inc.
Ticker symbol: FILM
Last price: $0.0165

FILM is in the business of financing media productions, specifically the financing of production ready, independent films and media projects that have potential for financial success.

FILM is already racking up the credits, which has investors excited.

• “Dead Air” (Executive Producer)
• “Behind Glass Walls” (Executive Producer)
• “Deposito Barbae” (Associate Producer)
• “The Fool” (Executive Producer);
• “Amara” (Producer);
• “Average & Uninteresting” (Associate Producer);
• “The Wild Adventures of BeBop Fuzz” (Associate Producer);
• “Sandal Brigade” (Series Producer)

Some of Hollywood’s biggest films of all time were independent movies.  We’re sure hits like: The Blair Witch Project, Reservoir Dogs, Clerks, The Terminator, The Passion of the Christ, and Slumdog Millionaire all ring a bell.

History has proven to us that many low-budget independent films can turn into box office smash hits and that’s what makes FILM so attractive.

So let’s recap:
• FILM made big headway in 2014 and is set up for an even bigger 2015.
• FILM trades under 2 cents a share so every uptick means real money in your pocket.
• FILM is coming off its recent lows with much upside potential ahead.
• FILM is receiving a ton of exposure and that should create some great trade opportunities this Friday.

Make sure you’re ready to book your profits with FILM!

Free Stock TipsAs always, do your own research, don’t chase gaps, use limit orders to enter positions, always use stop loss orders to protect your position, and take profits when you are in a position to do so.

Good Trading

Hi Everybody,

We brought you this one back in January, Star Mountain Resources, Inc. (SMRS). Since our alert the stock is up 25% and continues to gain traction.

Our alert for Wednesday is:
Star Mountain Resources, Inc.
Ticker symbol: SMRS
Last price: $1.25

SMRS is a junior mining company currently exploring the Chopar Project in the Star Mining District of Utah. The company has found the potential for skarn bodies on the property. CEO Joseph Marchal was quoted saying “Where there’s skarn, there’s gold.”

SMRS stands out amongst the 3000 or so other junior mining companies because their management staff combines a strong foundation of geological expertise to be able to identify and strategize mining opportunities, with the financial acumen to be able to reach viability with their projects.

When considering an investment in a microcap company, you start with the management, particularly a junior mining company since it is a “knowledge-based business”. SMRS’s management has the kind of credentials we like to see in long term ideas.

Make sure you’re ready to book your profits with SMRS!

Free Stock TipsAs always, do your own research, don’t chase gaps, use limit orders to enter positions, always use stop loss orders to protect your position, and take profits when you are in a position to do so.

Good Trading

Hi Everybody,

We’ve found a junior mining company that has unbelievably strong management, excellent transparency, which is another great sign for a long term idea, and a high potential project they’re working on that could eventually attract a buyout from the majors.

Our alert for Tuesday is:
Star Mountain Resources, Inc.
Ticker symbol: SMRS
Last price: $1.00

SMRS is a junior mining company currently exploring the Chopar Project in the Star Mining District of Utah.

SMRS stands out amongst the 3000 other junior mining companies because their management staff combines a strong foundation of geological expertise to be able to identify and strategize mining opportunities, with the financial acumen to be able to reach viability with their projects.

The leader in the mining industry, Rick Rule of Sprott Global Resource Investments Ltd. said “The first thing you should know is that the minerals exploration business is frequently mistaken for an asset-based business, but it’s really a knowledge-based business.”

When considering a true investment in a microcap company, you start with the management, particularly a junior mining company since it is a “knowledge-based business”. SMRS’s management has the kind of credentials we like to see in long term ideas.

We are initiating coverage on Star Mountain Resources, Inc. (SMRS), and plan to follow this company for a long time, stay tuned for updates on the company’s progress, and start doing your due diligence right now, because the earlier you decide, the more profit potential you’ll realize.

Make sure you’re ready to book your profits with SMRS!

Free Stock TipsAs always, do your own research, don’t chase gaps, use limit orders to enter positions, always use stop loss orders to protect your position, and take profits when you are in a position to do so.

Good Trading

Buy PharmaCyte Biotech

In: Tips

20 Jan 2015

Hi Everybody,

Our alert for Tuesday is:
PharmaCyte Biotech, Inc..
Ticker symbol: PMCB
Last price: $0.1675

PMCB is a clinical stage biotechnology company developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology Cell-in-a-Box®.

PMCB’s Cell-in-a-Box® is a way to enclose living cells in protective “cocoons” about the size of the head of a pin. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This “targeted chemotherapy” has proven remarkably effective in past clinical trials.

Reasons why should you be buying this stock:

1. This technology shows great promise. As a matter of fact, in the first round of testing patients received two courses of ifosfamide at one-third the regular dose plus a urological protectant after transplantation of 300 capsules. Median survival after diagnosis rose to 40 weeks, compared with historical control of 28 weeks with gemcitabine, and 1-year survival increased to 36%, compared with 18% for gemcitabine.

2. The European Medicines Agency (The European version of the FDA) has fast-tracked this treatment in order to cut the time it takes to get to market. That is obviously a great thing for patients and investors.

3. PMCB’s cell-in-a-box technology was named a Near Term Approach in the the Journal of the National Cancer Institute. The JNCI was established in 1940 and is internationally acclaimed as the source for the most up-to-date news and information from the rapidly changing fields of cancer research and treatment. Coverage in the Journal of the National Cancer Institute brings the kind of credibility that investors like to see when making long term bets on microcap companies.

This is why we’re excited to bring you a company in phase 2b of clinical trials for treating the terrible disease.

So while their current clinical trials are centered around the ability to treat pancreatic cancer, there is potential for this technology to treat several forms of cancer.

Biotechs can yield some of the largest returns out of any other industry in the microcap space, so when we find one with a story like this, we get pretty excited.

Make sure you’re ready to book your profits with PMCB!

Free Stock TipsAs always, do your own research, don’t chase gaps, use limit orders to enter positions, always use stop loss orders to protect your position, and take profits when you are in a position to do so.

Good Trading


Categories

Thanks to our sponsors